Login| Sign Up| Help| Contact|

Patent Searching and Data


Matches 101 - 150 out of 103,279

Document Document Title
WO/2014/180327A1
The present invention relates to a phenol derivative, a method of preparing same, and a pharmaceutical application of same, and more particularly, the present invention relates to a compound shown by the general formula (I) or a stereois...  
WO/2014/177490A1
The invention relates to a compound of formula (I) wherein A and R1 to R4 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2014/177527A1
The invention relates to a compound of formula (I) wherein A and R1 to R3 are defined as in the description and in the claims. The compound of formula (I) can be used as a medicament.  
WO/2014/177060A1
The present invention provides for compounds of Formula I-I and embodiments and salts thereof for the treatment of diseases (e.g., neurodegenerative diseases). R 1, R 2, R 3, X 1, X 2, A and Cy variable in Formula (I-I) all have the mean...  
WO/2014/179551A1
A method and associated system of treating a plant material consisting essentially of the plant cannabis in order to extract cannabinoids in liquid form from the plant material. The method includes heating the plant material; drying the ...  
WO/2014/178892A1
Described herein is the use of sobetirome for the treatment of neurodegenerative disease involving demyelination or other abnormalities with oligodendrocyte function, including but not limited to X-linked adrenoleukodystrophy (X-ALD), mu...  
WO/2014/176632A1
In alternative embodiments, the invention provides compositions and methods for treating, ameliorating and preventing various disorders and conditions in mammals, including genetically-predisposed and chronic disorders, where the microbi...  
WO/2014/177676A1
An effective dose of fenfluramine or its pharmaceutically acceptable salt for use in a method of treating and/or preventing Dravet Syndrome in a patient such as a patient previously diagnosed with Dravet Syndrome.  
WO/2014/176942A1
Disclosed is the use of an asparagus powder in medicines for the treatment of anxiety and depressive mental disorders, and in food and health foods, with the content of active ingredients contained in the asparagus powder being as follow...  
WO/2014/178803A1
The invention relates to a composition formed for use in the treatment of the alcohol addiction.  
WO/2014/178931A1
Methods of treating a subject having or at risk of developing a neurodegenerative disease or condition associated with demyelination, insufficient myelination, or underdevelopment of myelin sheath are described. The methods include admin...  
WO/2014/177977A1
The present invention is directed to a new class of triazine derivatives as described by formula (I) below in which A, X, R1, R2, R3, and R4 are as defined herein and to the use of the compounds as PDE10 inhibitors.  
WO/2014/177042A1
Provided in the present invention is a linker and a preparation method thereof, wherein one end of the linker may covalently link a small molecule compound and the like and the other end may specifically and covalently link a targeting s...  
WO/2014/178954A1
Described herein are compounds of Formula (I), pharmaceutically acceptable salts thereof, and pharmaceutical compositions thereof. Compounds described herein are useful for inhibiting arginine methyltransferase activity. Methods of using...  
WO/2014/177286A1
The invention relates to the use of biotin for treating X-linked adrenoleukodistrophy, in particular adrenomyeloneuropathy.  
WO/2014/177491A1
Title: New Solid Form of 1-(2-((2,4-Dimethylphenyl)thio)phenyl)piperazine Hydrobromide The present invention relates to 1-(2-((2,4-dimethylphenyl)thio)phenyl)piperazine hydrobromide (vortioxetine hydrobromide,a drug for the treatment of ...  
WO/2014/177524A1
The present invention provides for pyrimidine compounds of Formula (I-I) and embodiments thereof. In Formula (I-I) in which R1, R2, R3, R4, R5, R6' m, n and the "het" ring are as described herein. Also provided are pharmaceutical composi...  
WO/2014/177127A1
The invention relates to an agent for the prophylaxis and/or treatment of HIV and other viral infections. The agent contains, in particular, at least one peptide with an amino acid sequence suitable for the prophylaxis of fibrilla associ...  
WO/2014/179592A1
Embodiments of bridged tetrahydroisoquinolines and methods for their use in selectively inhibiting nicotinamide adenine dinucleotide phosphate (NADPH) oxidase 2 are disclosed. The disclosed compounds have a structure according to general...  
WO/2014/175713A1
The present invention relates to a pharmaceutical composition comprising a 5-membered heterocyclic compound, having an analgesic effect, and a derivative thereof. More particularly, the present invention relates to a preparation method f...  
WO/2014/173900A1
The present invention relates to a compound which is an antagonist of NR2C/D receptor or an inhibitor of the NR2C/D receptor expression for use in prevention and or treatment of epileptic seizures.  
WO/2014/175375A1
Provided are: a novel method for diagnosing adult T cell leukemia, a diagnosis kit therefor; a method for screening a therapeutic agent therefor; and a therapeutic agent. The expression level of SCYL2 gene in cells is detected and the de...  
WO/2014/172759A1
The present invention relates to chemical compounds useful in the positive modulation of the alpha 7 nicotinic acetylcholine receptor (α7 nAChR).  
WO/2014/175773A1
The invention relates to the field of the pharmaceutical industry and food industry and concerns a formula for restoring normal sleep as well as biological rhythms in humans and/or relieving conditions associated with the use of alcohol ...  
WO/2014/175518A1
The present invention provides a composition for relieving, preventing, or treating pain containing a mate extract as an active ingredient. The composition of the present invention has effects of relieving and treating pain that has occu...  
WO/2014/176309A1
The present invention provides methods and compositions comprising ALDH2 in the treatment of a patient with toxicity resulting from ALDH2 deficiency. The physiological states that may be treated using the present invention include tempor...  
WO/2014/174834A1
Provided is a therapeutic agent for neurological disorder, said therapeutic agent directly acting on vascular barrier failure that depends on oxygen concentration. The therapeutic agent for neurological disorder comprises, as an active i...  
WO/2014/176149A4
Andrographolide binds to GSK-3Beta, preventing changes in neuropathology in an Alzheimer's model, reducing Amyloid-Beta peptide levels, changing the ontogeny of hippocampus and cortex amyloid plaques, and reducing tau phosphorylation aro...  
WO/2014/174564A1
The purpose of the present invention is to provide an adhesive patch drug formulation containing memantine or a pharmaceutically acceptable salt thereof, adhesive patch drug keeping sublimation of the memantine during manufacture may to ...  
WO/2014/176149A1
Andrographolide binds to GSK-3Beta, preventing changes in neuropathology in an Alzheimer's model, reducing Amyloid-Beta peptide levels, changing the ontogeny of hippocampus and cortex amyloid plaques, and reducing tau phosphorylation aro...  
WO/2014/170319A1
The invention refers to a combination comprising a Sigma ligand of general formula (I) and alpha-2-adrenergic agonist compound, a medicament comprising said active substance combination, and the use of said active substance combination f...  
WO/2014/171828A1
The present invention relates to food compositions comprising nutritional composition for use in the treatment or nutritional management of phenylketonuria or hyperphenylalaninemia or for preserving or improving brain function in PKU or ...  
WO/2014/172482A1
The invention is directed to novel compounds, formulations containing said compounds or pharmaceutically acceptable salts thereof which are suitable for administration to a patient.  
WO/2014/171542A1
The present invention provides a controlled-release solid drug formulation containing pioglitazone or a salt thereof as an active ingredient, and having exceptional sustained release properties. The controlled-release solid drug formulat...  
WO/2014/172266A1
Disclosed herein are methods and compositions related to therapeutic use of aminopyridines in patients with stroke-related impairments, in particular, in patients with sensorimotor impairments resulting from certain types of stroke.  
WO/2014/170494A1
The present invention relates to new tricyclic triazolic compounds of formula (I) having a great affinity for sigma receptors, especially sigma-1 receptors, as well as to the process for the preparation thereof, to compositions comprisin...  
WO/2014/172478A1
The aspects of the disclosed embodiments are directed to novel compounds, specifically, quaternary ammonium derivatives of tertiary amine containing opioid drug compounds such as hydrocodone, hydromorphone and oxycodone, formulations con...  
WO/2014/169833A1
Provided herein are 19-nor C3,3-disubstituted C21-pyrazolyl steroids of Formula (I), and pharmaceutically acceptable salts thereof; wherein-, R1, R2, R3a, R3b, R4a, R4b, R5, R6, and R7are as defined herein. Such compounds are contemplate...  
WO/2014/171781A1
The present invention relates to a composition including a Laurus nobilis leaf extract as an active ingredient, and particularly, to a composition for preventing or treating hangover including the Laurus nobilis leaf extract, a food comp...  
WO/2014/170902A1
The present invention provides cannabinoid type 2 (CB2) receptor inverse agonists for treating or ameliorating psychiatric disorders. The present invention further provides pharmaceutical compositions comprising 4'-O-methylhonokiol for t...  
WO/2014/169832A1
Provided herein are 3,3-disubstituted 19-nor-steroidal compounds according to Formula (I): and pharmaceutical compositions thereof. Such compounds are contemplated useful for the prevention and treatment of a variety of CNS-related condi...  
WO/2014/171583A1
The present invention relates to a composition for preventing and/or treating a stroke or a degenerative brain disease comprising: at least two substances selected from the group consisting of egg yolk lecithin, glycerol, sodium oleate, ...  
WO/2014/171813A1
The present invention relates to food compositions comprising nutritional composition for use in the treatment of phenylketonuria or hyperphenylalaninemia or for preserving or improving brain function in PKU or hyperphenylalaninemia. The...  
WO/2014/169831A1
Provided herein are19-nor C3,3-disubstituted steroids of Formula (I): and pharmaceutically acceptable salts thereof; wherein, ⃜⃜, R1, R2, R3a, R3b, R4a, and R 4bare as defined herein, and A is a carbon bound substituted or unsubstitu...  
WO/2014/170343A1
The present invention relates to a composition comprising a depolarizing agent acting on a receptor expressed by the dopamine neurons of the substantia nigra, and a modulator of the nicotinic cholinergic pathway, wherein said receptor ex...  
WO/2014/171434A1
The present invention addresses the issue of providing an anti-Alzheimer's agent that uses an amyloid β-protein as the mechanism of action therefor but that is different from conventional mechanisms of action. This therapeutic agent for...  
WO/2014/170352A1
The present invention relates to nalmefene for use in the treatment of anxiety disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid anxiety disord...  
WO/2014/170353A1
The present invention relates to nalmefene for use in the treatment of sleep disorders. The present invention further relates to nalmefene for use in the treatment of patients with alcohol dependence who have a co-morbid sleep disorder. ...  
WO/2014/170521A1
The invention relates to the use of protein particles generated from recombinant pion protein (rPrP) subjected to a polymerisation process for the treatment and/or prevention of prion diseases. Such particles behave as an "attenuated" pr...  
WO/2014/170248A1
The present invention is directed to arylpyrrolopyridine derivatives of formula (A) (A). The compounds are considered useful for the treatment of diseases associated with LRRK2 such as Lewy body dementia, Parkinson's disease cancer.  

Matches 101 - 150 out of 103,279